Skip to Content

Farydak Approval History

Farydak (panobinostat) is a histone deacetylase inhibitor for the combination treatment of multiple myeloma.

Development History and FDA Approval Process for Farydak

Feb 23, 2015Approval FDA Approves Farydak (panobinostat) for Multiple Myeloma
Nov  6, 2014Novartis Announces Outcome of FDA Advisory Committee Meeting for LBH589 (Panobinostat)

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.